Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty

• Status: Completed
• Trial end date: 2017-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare intravenous Tranexamic Acid (TXA) versus normal saline placebo to determine whether or not TXA administration reduces blood loss, decrease in hemoglobin, and rate of transfusions following anatomic and reverse total shoulder arthroplasty (TSA) surgeries.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Rush University Medical Center
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Any patient scheduled for a primary anatomic or reverse TSA

Exclusion Criteria:

• Allergy to TXA

• Acquired disturbances of color vision

• Pre-op use of anticoagulant therapy within five days before surgery

• History of arterial or venous thromboembolic disease; such as DVT, PE, CVA, TIA

• Pregnancy or breastfeeding

• Recent MI (within 6 months of surgery) or any placement of stent regardless of time since placement

• Renal impairment

• Refusal of blood products

• Any patient undergoing a revision TSA

• Patients who decline to participate